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Sub-Saharan Africa has the highest Human Immunodeficiency Virus (HIV) prevalence and the 
second highest Hepatitis B virus (HBV) and Hepatitis C virus (HCV) prevalence in the world.  
Co-infection of HIV, HBV and HCV occurs due to shared transmission routes and common risk 
factors.  
Existing studies from sub-Saharan Africa show wide variations in the prevalence of co-
infections, depending on age, gender, race and geographical area.  
Aim 
The aim of this study was to describe HIV and HBV/HCV co-infections in KwaZulu-Natal from 
2002 to 2010 using a laboratory database. 
Methods 
An observational, analytical, retrospective study design was used.  The study setting was the 
National Health Laboratory Service Department of Virology, in Durban. The study population 
consisted of 507 834 individuals (all those with HIV, HBV or HCV test results from 2002 to 
2010 recorded in the database).  
Results 
The overall sero-prevalence of HIV was 47%, HBV:12.05% and HCV:4.13%.  The highest sero-
prevalence of HIV and HCV was in the 30-35 year age group; for HBV it was in the 20-25 year 
age group. HIV sero-prevalence was higher in females, while HBV and HCV sero-prevalence 
was higher in males.  
The uThukela, Amajuba and Zululand health districts had the highest HIV, HBV and HCV sero-
prevalence respectively. The sero-prevalence of HIV and HBV has decreased significantly over 
time, while there was no significant change in the sero-prevalence of HCV. 
iii 
 
Compared to those without HIV, individuals with HIV had increased odds of being positive for 
hepatitis markers: 3.19 for Hepatitis B surface antigen, 2.06 for Hepatitis B e antigen and 2.91 
for HCV. Those with HIV were less likely to be positive for Hepatitis B surface antibodies. 
Those with Hepatitis B had a 1.38 times the odds of being co-infected with HCV compared to 
those without HBV. 
Discussion 
This study documented the high sero-prevalence of HIV, HBV and HCV over 9 years for 
KwaZulu-Natal. A significant number of HIV positive individuals are co-infected with either 
HBV or HCV.  
Recommendations 
The results of this study may guide public health decisions on the approach to diagnosis, 










I, Nerisha Tathiah declare that: 
 
i. The research reported in this dissertation, except where otherwise indicated, and is my 
original research. 
 
ii. This dissertation has not been submitted for any degree or examination at any other 
university. 
 
iii. This dissertation does not contain other persons’ data, pictures, graphs or other information, 
unless specifically acknowledged as being sourced from other persons. 
 
iv. This dissertation does not contain other persons’ writing, unless specifically acknowledged as 
being sourced from other researchers. Where other written sources have been quoted, then: 
a) their words have been re-written but the general information attributed to them has 
been referenced; 
b) where their exact words have been used, their writing has been placed inside 
quotation marks, and referenced. 
 
v. Where I have reproduced a journal publication of which I am an author, I have indicated in 
detail which part of the publication was actually written by me alone and not by other 
authors, editors or others.  
 
vi. This dissertation does not contain text, graphics or tables copied and pasted from the Internet, 









Student: Dr Nerisha Tathiah 
Date: April 19, 2017 
 
Discipline of Public Health Medicine, 
School of Nursing and Public Health 
College of Health Sciences 
University of KwaZulu-Natal South Africa 
 
Signature:  
Supervisor: Dr C. Bagwandeen 
 
Signature:  








I would like to acknowledge the support of the academic and administrative staff at the 
Discipline of Public Health Medicine. 
 
I would like to extend my appreciation to the Department of Virology, Inkosi Albert Luthuli 
Central Hospital, National Health Laboratory Service for access to and use of the virology 
database. 
 
I would like to thank my family, especially my parents Mr R.N. Tathiah and Mrs D. Tathiah, and 





PUBLICATIONS OR PRESENTATIONS 
 
Publication 
N Tathiah, R Parboosing, L Singh, CC Jinabhai, P Moodley. HIV and Hepatitis B/C co-infection 
in KwaZulu-Natal, South Africa: a retrospective database analysis. South African Journal of  
Infectious Diseases 2014; 29(1):19-22. 
 
Conference presentation 
Dr N Tathiah, Dr R Parboosing, Ms L Singh, Prof CC Jinabhai, Dr P Moodley. The sero-
prevalence of Hepatitis A, B and C in HIV positive and negative patients in KwaZulu-Natal for 
the period 2002-2010: a retrospective database study. Oral presentation, 28-30 November 2011. 




ACRONYMS AND ABBREVIATIONS 
 
AIDS - Acquired Immunodeficiency Syndrome 
ARVs - Antiretrovirals 
ART - Antiretroviral Therapy 
CI - Confidence Interval 
ELISA - Enzyme-Linked Immunosorbent Assay 
HBeAg - Hepatitis B e antigen 
HBsAb - Hepatitis B surface antibody 
HBsAg - Hepatitis B surface antigen 
HIV - Human Immunodeficiency Virus 
HBV - Hepatitis B Virus 
HCV - Hepatitis C Virus  
HIV - Human Immunodeficiency Virus 
IgG - Immunoglobulin G 
KZN - KwaZulu-Natal  
LIS – Laboratory Information System 
MTCT – Mother to Child Transmission 
NHLS - National Health Laboratory Service 
OR - Odds Ratio 
PCR - Polymerase Chain Reaction 
ix 
 
RR - Risk Ratio 
SANAS - South African National Accreditation System 
WHO - World Health Organization 
x 
 
TABLE OF CONTENTS 
 
ABSTRACT ............................................................................................................................... ii 
DECLARATION ...................................................................................................................... iv 
ACKNOWLEDGEMENTS ..................................................................................................... vi 
TABLE OF CONTENTS .......................................................................................................... x 
FIGURES ................................................................................................................................ xiv 
1 CHAPTER I: INTRODUCTION ......................................................................................... 1 
1.1 INTRODUCTION ........................................................................................................... 1 
1.2 BACKGROUND .............................................................................................................. 1 
1.3 STATEMENT OF THE PROBLEM ........................................................................... 16 
1.4 PURPOSE OF THE RESEARCH ............................................................................... 17 
1.5 SPECIFIC OBJECTIVES OF THE RESEARCH ..................................................... 17 
1.6 ASSUMPTIONS UNDERLYING THE STUDY ........................................................ 17 
1.7 OPERATIONAL DEFINITIONS USED IN THE STUDY ....................................... 17 
1.8 ORGANISATION OF THE REPORT ........................................................................ 18 
1.9 SUMMARY .................................................................................................................... 19 
2 CHAPTER II: LITERATURE REVIEW .......................................................................... 20 
2.1 INTRODUCTION ......................................................................................................... 20 
2.2 PURPOSE OF THE LITERATURE REVIEW ......................................................... 20 
2.3 SCOPE OF THE LITERATURE REVIEW ............................................................... 20 
2.4 SOURCES OF LITERATURE REVIEWED ............................................................. 20 
2.5 LITERATURE REVIEWED........................................................................................ 21 
2.6 SUMMARY .................................................................................................................... 31 
3 CHAPTER III: METHODS ................................................................................................ 32 
3.1 INTRODUCTION ......................................................................................................... 32 
3.2 TYPE OF RESEARCH ................................................................................................. 32 
3.3 STUDY DESIGN ........................................................................................................... 32 
3.4 STUDY SETTING ......................................................................................................... 32 
3.5 TARGET POPULATION ............................................................................................. 33 
xi 
 
3.6 STUDY POPULATION ................................................................................................ 33 
3.7 SAMPLING .................................................................................................................... 33 
3.8 DATA SOURCES .......................................................................................................... 34 
3.9 VARIABLES .................................................................................................................. 35 
3.10 BIAS AND LIMITATIONS ........................................................................................ 36 
3.11 STATISTICAL ANALYSIS ....................................................................................... 38 
3.12 ETHICS ........................................................................................................................ 38 
3.13 SUMMARY .................................................................................................................. 39 
4 CHAPTER IV: RESULTS .................................................................................................. 40 
4.1 INTRODUCTION ......................................................................................................... 40 
4.2 STUDY SAMPLE .......................................................................................................... 40 
4.3 PRESENTATION OF DATA ....................................................................................... 40 
4.4 SUMMARY .................................................................................................................... 50 
5 CHAPTER V: DISCUSSION .............................................................................................. 51 
5.1 INTRODUCTION ......................................................................................................... 51 
5.2 FINDINGS ...................................................................................................................... 51 
5.3 VALIDITY ..................................................................................................................... 56 
5.4 BIAS AND LIMITATIONS .......................................................................................... 58 
5.5 SUMMARY .................................................................................................................... 59 
6 CHAPTER VI: RECOMMENDATIONS AND CONCLUSIONS .................................. 60 
6.1 INTRODUCTION ......................................................................................................... 60 
6.2 CONCLUSION .............................................................................................................. 60 
6.3 RECOMMENDATIONS .............................................................................................. 61 
6.4 RECOMMENDATIONS FOR FURTHER STUDY .................................................. 63 
7 REFERENCES ..................................................................................................................... 65 
8 APPENDIX ........................................................................................................................... 73 
APPENDIX A ....................................................................................................................... 73 








Table 1: Comparison of studies discussed in the literature review ............................................... 29 
Table 2: Sensitivities and specificities of HIV, HBV and HCV assays that were used in this study
....................................................................................................................................................... 36 
Table 3: Number and % of individuals with HIV, HBV or HCV serological tests in the study 
population, from 2002 to 2010...................................................................................................... 41 
Table 4: HIV, HBV and HCV sero-prevalence for the study population from 2002 to 2010 ...... 42 
Table 5: Comparison of hepatitis markers between HIV positive and HIV negative individuals, in 
the study population from 2002 to 2010 ....................................................................................... 49 
Table 6: Association between HBV and HCV sero-prevalence in the study population from 2002 
to 2010 .......................................................................................................................................... 49 
Table 7: Age distribution of the study population from 2002 to 2010 ......................................... 77 
Table 8:  Age categories for individuals with HIV, HBV and HCV serological tests in the study 
population from 2002 to 2010....................................................................................................... 77 
Table 9: Gender distribution of individuals with HIV, HBV and HCV serological tests in the 
study population from 2002 to 2010 ............................................................................................. 78 
Table 10: Number and % of  individuals with HIV, HBV or HCV serological tests in 11 KZN 
health districts for the study population from 2002 to 2010 ......................................................... 79 
Table 11: HIV results, by age categories for the study population from 2002 to 2010 ................ 79 
Table 12: HBV results, by age categories for the study population from 2002 to 2010 .............. 80 
Table 13: HCV results, by age categories for the study population from 2002 to 2010 .............. 81 
Table 14: HIV, HBsAg and HCV IgG results, by gender for the study population from 2002 to 
2010............................................................................................................................................... 82 
Table 15: HIV results, by female gender and age categories for the study population from 2002 
to 2010 .......................................................................................................................................... 84 
Table 16: HIV results, by male gender and age categories for the study population from 2002 to 
2010............................................................................................................................................... 85 
Table 17: HBV results, by female gender and age categories for the study population from 2002 
to 2010 .......................................................................................................................................... 86 
xiii 
 
Table 18: HBV results, by male gender and age categories for the study population from 2002 to 
2010............................................................................................................................................... 87 
Table 19: HCV results, by female gender and age categories for the study population from 2002 
to 2010 .......................................................................................................................................... 88 
Table 20: HCV results, by male  gender and age categories for the study population from 2002 to 
2010............................................................................................................................................... 89 
Table 21: HIV results, by health district for the study population from 2002 to 2010 ................. 90 
Table 22: HBsAg results, by district for the study population from 2002 to 2010....................... 90 
Table 23: HCV IgG results, by district for the study population from 2002 to 2010 ................... 91 
Table 24: HIV results for the study population, from 2002 to 2010............................................. 92 
Table 25: HBV results for the study population, from 2002 to 2010 ........................................... 92 







Figure 1: HIV sero-prevalence (with 95% CI) by age and gender for the study population from 
2002 to 2010 ................................................................................................................................. 43 
Figure 2: HBV sero-prevalence (with 95% CI) by age and gender for the study population from 
2002 to 2010 ................................................................................................................................. 43 
Figure 3: HCV sero–prevalence (with 95% CI) by age and gender for the study population from 
2002 to 2010 ................................................................................................................................. 44 
Figure 4: HIV, HBV and HCV sero-prevalence in 11 KZN health districts from 2002 to 2010..45 
Figure 5: HIV, HBV and HCV sero-prevalence for the study population from 2002 to 2010 ..... 46 
Figure 6: HIV sero – prevalence for the study population from 2002 to 2010 ............................. 46 
Figure 7: HBV sero–prevalence for the study population from 2002 to 2010 ............................. 47 




1 CHAPTER I: INTRODUCTION 
1.1 INTRODUCTION 
Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) and Hepatitis C virus (HCV) 
are important global public health problems.  Sub-Saharan Africa has the highest HIV 
prevalence, as well as the second highest HBV and HCV prevalence in the world 1-3.   
Co-infection of HIV, HBV and HCV is due to shared transmission routes and common risk 
factors. HIV affects the epidemiology and worsens disease progression in HBV and HCV co-
infected individuals.  The increased access to antiretroviral therapy (ART) has extended the life 
expectancy of those living with HIV. However, there is a greater potential for morbidity due to 
drug interactions and treatment side effects in those with co-infections 1, 4. 
The majority of previous studies on HIV, HBV and HCV co-infections are from high income 
settings and focus on high risk groups.  There are differences between mode and time of 
transmission between high and middle to low income countries. Existing studies from sub-
Saharan Africa show a wide variation in the prevalence of co-infections, depending on age, 
gender, race and geographical area 5. There is a paucity of population based data on the 





Over the past three decades, HIV has been responsible for more than 25 million deaths, 
worldwide 2.  In 2012, there were approximately 35.3 million (95% Confidence Interval (CI) 
32.2-38.8 million)  people living with HIV; of these more than 9.7 million people were receiving 
ART in low and middle income countries 2. Furthermore, the burden of HIV has a 
disproportionate effect on sub-Saharan Africa; in 2012, 70% of all new HIV infections occurred 




South Africa has one of the fastest growing HIV epidemics in the world, and is currently the 
country with the highest number of people living with HIV 6. According to 2011 estimates from 
the WHO/UNAIDS Reference Group, 5 600 000 people were living with HIV and AIDS in 
South Africa 7; 270 000 South Africans  died of AIDS-related causes, and 1.79 million (95% CI 
1.65-1.93 million) people were on ART 8.   
The rollout of ART in South Africa is associated with an 11.3 year gain in adult life expectancy. 
In 2003, prior to ART being available in the public health sector, adult life expectancy was 49.2 
years; by 2011, adult life expectancy increased to 60.5 years 9. 
A defining feature of the South African HIV epidemic is the burden of HIV infections in young 
women, with the additional implications for Mother to Child Transmission (MTCT). HIV 
infection is three to six times higher in female than male adolescents; this difference is due to 
sexual relationships between young women and older men. The high HIV prevalence, concurrent 
and total number of sexual relationships and other sexually transmitted diseases and population 
mobility further increase the probability of HIV infection in South Africa 10. 
The HIV prevalence in South Africa varies by age, gender and geographic area 6. Data from the 
2011 National Antenatal Survey (used as a proxy indicator for monitoring the spread of HIV in 
the heterosexual population) indicated a stable HIV prevalence of 29.5% (95% CI 28.7%-
30.2%), among pregnant women (aged 15-49 years) attending antenatal clinics in the public 
sector 11. Nationally, there was a slight decrease in the HIV prevalence among the 15-19 year age 
group to 12.7% (95% CI 11.8%-13.6%) while  HIV prevalence among the 30-34 year age group 
had increased to 42.2% (95% CI 40.6%-43.7%) 11. 
The 2011 HIV prevalence in KwaZulu-Natal (KZN) was the highest in the country (37.4%, 95% 
CI 35.8%-39.0%), compared to Western Cape (18.2%, 95% CI 14.3%-22.8%). Within KZN, 
there was also variation between districts. uMzinyathi district had the lowest HIV prevalence 
24.6 % (95% CI 20.4%-29.4%), with Ugu and uMkhanyakude districts each having a prevalence 







The transmission of HIV involves the direct transfer of genital, rectal or oral fluids through 
sexual intercourse, sharing of blood-contaminated needles, maternal (in utero, intrapartum, 
postpartum - breastfeeding), and medical procedures (e.g. transfusions or exposure to 
contaminated instruments) 12.  
Factors that increase the risk of contracting HIV include: unprotected intercourse; sexually 
transmitted infections; contaminated  injection equipment;  blood transfusions, unsterile cutting 
or piercing; and accidental needle stick injuries  among health care workers 12. 
HIV has spread in two epidemiologically distinct patterns: (1) Men having sex with men (MSM) 
intercourse, or contact with infected blood (e.g. through sharing needles in injection drug users; 
and through transfusions, prior to the effective screening of donors), and (2) heterosexual 
intercourse. In most countries, both patterns occur, but the first pattern usually predominates in 
higher income countries; the second pattern predominates in sub-Saharan Africa, South America, 
and southern Asia 12. 
The HIV epidemic in South Africa before 1987 was concentrated among MSM, and recipients of 
blood products 6. Once HIV was introduced into the heterosexual population, prevalence 
increased exponentially (1995 to 2000) 6. Since 2000, the rate of increase has slowed 
substantially, though there is still the continuing problem of large numbers of new HIV 
infections 6. In 2001 South Africa implemented a MTCT programme to prevent HIV 
transmission from mother to child 13. In 2012, the national MTCT of HIV was 3.5% (95% CI 
2.9%-4.1%); for the same period the MTCT of HIV for KZN was 2.9 (95% CI 1.7%-4.0%) 13. 
Clinical 
HIV is a RNA retrovirus that targets CD4+ lymphocytes and impairs cell-mediated immunity. 
Manifestations range from asymptomatic carriage to AIDS (Acquired Immune Deficiency 
Syndrome), which is defined by serious opportunistic infections or a CD4 count of < 200 
cells/μl. The widespread availability of life saving ART ensures an increased life expectancy in 





Laboratory diagnosis  
There are two approaches to the diagnosis of HIV: the detection of the virus itself (HIV RNA or 
p24 antigen testing), and the detection of an immunological response to the virus, using ELISA 
(Enzyme-Linked Immunosorbent Assay) tests. False negatives may occur during the “window 
period" of 3 to 6 weeks during which antibodies to HIV are not yet detectable. Early diagnosis 
relies on the detection of viral antigen or HIV RNA. A diagnosis of MTCT uses nucleic acid 
testing, or antibodies in the case of infants >15 (or 18 months). Prevalence assessments are 
generally based on antibody testing 14. 
Treatment 
While there is no cure for HIV, the viral load can be suppressed below detectable limits by 
combination ART consisting of three or more antiretrovirals (ARVs) 6.  
Prevention 
Individuals can reduce the risk of HIV infection by the use of male and female condoms 15, 
voluntary medical male circumcision16, 17, harm reduction for injecting drug users 15; and the use 
of ARVs (either as pre-exposure oral prophylaxis in individuals engaging in risky behaviours 18, 
or as post-exposure prophylaxis in healthcare workers with needlestick injuries 19, or in      
MTCT 13). 
 
 1.2.2. HBV 
Epidemiology 
Globally, 350 million people are chronically infected with HBV, of which 4 million are acute 
cases. One million people die per year due to the chronic consequences of HBV 1, 20. 
Based on the prevalence of chronic HBV infection, the world is divided into three areas: Low 
endemic  areas (<2% HBsAg prevalence), intermediate endemic areas (2-8% HBsAg prevalence) 




Low endemic areas include North America, Western and Northern Europe, Australia, and parts 
of South America.  Most infections occur in high risk populations (injection drug users, 
individuals with multiple sexual partners, and MSM) 1, 20. 
High endemic areas include almost three quarters of the world’s population - sub-Saharan Africa, 
Southeast Asia, Amazon Basin, Middle East, central Asian Republics and Eastern Europe.  In 
Asia, mother to child spread is very common 1, 20. In sub-Saharan Africa, especially in countries 
such as South Africa, Botswana, Zambia and Zimbabwe, HBV is most commonly spread by 
person to person contact in early childhood 21. 
The introduction of the Hepatitis B  vaccine into the Department of Health’s Expanded 
Programme on Immunisation (EPI) in 1995 has changed the epidemiology of HBV in South 
Africa 22. Prior to introduction of the Hepatitis B vaccine, 8-9% of children < 1 year of age were 
HBsAg positive 22, 23. Subsequent studies on vaccinated children have shown a much lower 
prevalence (range 0.0%-2.7%) 22, 24-27. 
South African HBV prevalence also differs based on age, gender, race and geographical location.  
In a study conducted on rural and urban children in KZN, 2.5% of the newborn to six years age 
group was HBsAg positive. The prevalence of HBsAg was highest in the 6-8 year age group and 
was 14.4% and 22.6% in urban and rural children respectively 28. In a subsequent study almost 
three quarters of the household contacts of infected children were found to have evidence of 
HBV infection 29.  A sero-prevalence  survey conducted in 1999 of children in the Eastern Cape, 
reported a HBV prevalence of 10.4% with a higher prevalence (15.7%) in 5-6 year olds 23.  
  
In adults, HBV prevalence ranged from 8.3% in women attending antenatal clinics, to 10% in 
mine workers 21. Although both sexes were exposed to HBV, males were more likely to develop 
chronic HBV infection than females (male to female ratio of 2.6:1) 22, 30. 
The prevalence of chronic HBV infection in black South Africans was estimated to range from 
9.6% to 14%, with 76% having previous exposure to HBV 22, 31. In contrast, the prevalence in 




HBV prevalence varied between rural and urban populations , with a prevalence of chronic HBV 
in the rural Eastern Cape of 15.5%, compared to urban areas such as Durban (7.4%) and Soweto 
(1.3%) 22, 32.  The prevalence of HBV varied in those without HIV: 10% in rural, and 1% in 
urban areas 33, 34. 
There are few representative studies on HBV prevalence in South Africa. 
Transmission 
HBV is transmitted through contact with blood or other body fluids of an infected person. HBV 
is 100 times more infectious than HIV. There are multiple routes for the transmission of HBV 
(mother to child, horizontal, sexual, injection drug use and iatrogenic) 1, 20, 35. 
Mother to child transmission occurs either in utero, during delivery or in the perinatal period, 
through the close contact between mother and baby 1, 20, 35. In South Africa, while mother to child 
transmission does occur, it  is not the major transmission route for HBV 22. 
The major route of transmission in South Africa occurs between toddlers and is horizontal in 
nature (unrelated to sexual, perinatal, or parenteral exposure). Transmission may occur through 
ritual scarification, open wounds and saliva. An estimated 20-30% of those horizontally infected 
before age 5 proceed to chronicity. HBV infection during early childhood can lead to adolescents 
being infected by the time they are sexually active. Sexual transmission is the predominant mode 
of transmission in adolescence and early adulthood, with 3-5% of those infected progressing to 
chronicity 22. 
Illicit injection drug use is an important route of transmission in low endemic areas. Iatrogenic 
transmission (through unsafe therapeutic injections and contaminated blood transfusions) are 
responsible for 21 million HBV infections each year, mostly in areas where HBV is highly 
endemic 1, 20, 35. However, in South Africa, the risk is reduced due to the screening of blood 
donations by nucleic acid testing. Nonetheless, South African healthcare workers and patients are 







HBV is a hepatotropic virus that causes a wide spectrum of liver disease ranging from an 
asymptomatic infection to acute liver failure or chronic liver disease 20, 35.  
HBV may be detected 30 to 60 days after infection and persists for variable periods of time. 
Symptoms of acute infection with HBV can last for weeks or persist for up to six months 20, 35. 
More than 90% of healthy adults who are infected with HBV will completely clear the virus 
within six months and will recover.  The remainder will develop chronic hepatitis or become 
inactive carriers. Cirrhosis can be a consequence of infection; hepatocellular carcinoma can 
develop in chronic HBV carriers, even without preceding cirrhosis 20, 35. 
The possibility that HBV infection becomes chronic depends upon the age at which a person 
becomes infected. Children who are infected before they are 6 years old  are the most likely to 
develop chronic infections: 80-90% of infants infected during the first year of life, and  30-50% 
of children infected before the age of 6 years will develop chronic infections.  In adults, 15-25% 
of those who are chronically infected during childhood will die from complications related to 
HBV 20.  
Chronic HBV infection is more likely to develop in those with congenital or acquired 
immunodeficiency (including HIV). Only those who develop antibodies following vaccination or 
infection are immune to HBV 20, 35.   
Laboratory diagnosis 
Laboratory diagnosis of HBV infection is based on the detection of the Hepatitis B surface 
antigen (HBsAg).  Acute HBV infection is identified by HBsAg, immunoglobulin M (IgM) 
antibody to Hepatitis B core antigen (HBcAg) and Hepatitis B e antigen (HBeAg), which is an 
indicator of active viral replication and greater infectivity. The HBeAg marker is more useful in 
prognosis than in diagnosis. Chronic liver disease develops more often among patients with 





Chronic infection is defined by HBsAg persistence beyond 6 months. In 5 to 10% of patients, 
antibodies do not develop and HBsAg persists; these patients become asymptomatic carriers or 
develop chronic hepatitis. HBsAg persistence is the most important indicator for the 
development of chronic liver disease and hepatocellular carcinoma later in life. HBV-DNA is 
detectable by Polymerase Chain Reaction (PCR) in patients with active HBV infection 20, 35. 
Surveillance 
South Africa has a system for the routine reporting of notifiable medical conditions, including 
Hepatitis B and C. This is a passive surveillance system managed by the National Department of 
Health (NDOH) 36. A challenge with such a passive reporting system is the associated under 
diagnosis and under reporting 37, 38.  
Treatment  
Individuals with chronic HBV can be treated with antiviral agents. Treatment cannot completely 
eradicate HBV but can slow the development of complications (including cirrhosis and 
hepatocellular carcinoma) thereby improving long term survival. Treatment is not accessible or 
available in many resource-constrained settings 20, 35.  
Prevention 
General prevention measures 
HBV transmission can be prevented by the implementation of quality assured blood safety 
strategies (including screening) and safe injection practices. Safer sexual practices also protect 
against transmission 20, 35. 
Vaccination 
The Hepatitis B vaccine is the foundation of Hepatitis B prevention.  The vaccine, available 
since 1982, has an excellent safety record and is 95% effective in preventing infection. It confers  
protection for at least 20 years, and in some cases may even be lifelong 20.  
The HBV vaccine was included in the South African EPI programme in 1995 and is given at 6, 




Africa was less than 75%, according to the 2012 WHO estimates 40. However, this may be an 
overestimate of coverage, and it has been recommended that high quality coverage surveys be 
conducted, to obtain an accurate assessment 22. 
HBV vaccination is recommended in the following individuals 39:  all infants, through the EPI; 
infants and adolescents not previously vaccinated; and individuals at increased risk of HBV 
infection as a result of percutaneous or mucosal exposure to blood or blood products, as well as 
those at risk of more severe infection. These include: healthcare workers (including student 
healthcare workers and domestic workers in healthcare facilities), injection drug users, MSM, 
patients in haemodialysis or oncology units, transplant candidates, household contacts and sexual 
partners of HBsAg-positive individuals, those receiving frequent blood or blood product 
transfusions, post exposure prophylaxis following occupational or sexual exposure and those 




Globally, 150 million people are chronically infected with HCV and are at risk of developing 
cirrhosis and/or hepatocellular carcinoma. About 3–4 million people are infected with HCV 
annually, of which more than 350 000 people die due to liver related  disease 1, 41.  
The estimated worldwide prevalence of HCV infection is 2.2%. The geographic differences in 
the prevalence of HCV infection (similar to HBV), are described: low prevalence (1.0-1.9%), 
moderate prevalence (2-2.9%), and high prevalence (>3%), However the regions differ from 
those for HBV 1, 41.  
Regions of low HCV prevalence are North America, northern and Western Europe.  Countries 
such as Canada, Germany, France and Australia report a 1% HCV prevalence 4. Illicit injection 
drug use is the predominant mode of transmission in most low prevalence areas 1, 41. 
The highest global HCV prevalence is in Asia, followed by Africa with the second highest 




(2.4-6.5%) 4.   HCV prevalence in sub-Saharan Africa is an estimated 5.3%;  Egypt has the  
highest reported prevalence (22%) 42.   
In South Africa, there is a wide variation in HCV prevalence, depending on age, gender, race, 
geographic location and risk groups. 
HCV prevalence increases with age, with a higher prevalence reported in the older than 40 year 
age group 42. 
HCV sero-prevalence in the blood donor population was found to be 0.16%, 0.34%, 0.75%, and 
0.22% for whites, Asians, Blacks, and Coloureds respectively 43. 
HCV antibodies were found in 1.8% of healthcare workers in a large urban referral hospital in 
South Africa 23.  The prevalence of HCV in a KZN study of urban and rural populations was 
1.7% (95% CI 0.0- 3.6%) and 0.9% (95% CI 0.1-1.7%) respectively 44.  
In high risk cohorts (those with liver disease, receiving multiple blood transfusions or blood 
products, on dialysis and renal transplant patients), the estimated HCV prevalence was 4.3-65% 
(mean of 23.5%). In low risk cohorts (such as blood donors) the estimated prevalence was    
0.1% 42. 
There are few representative HCV prevalence studies in South Africa. No cross sectional 
population surveys are available  and existing studies are limited geographically or to specific 
groups (e.g. high risk cohorts). 
Transmission 
HCV is ten times more infectious than HIV and is transmitted through contact with the blood or 
bodily fluids from an infected individual, though in 30-40% of infections the routes of  
transmission remain unknown.  There are multiple routes of transmission (iatrogenic, injection 
drug use, mother to child, and sexual) 1, 41.  
Iatrogenic transmission occurs via contaminated blood transfusions, blood products and organ 




In high income countries, iatrogenic and injection drug use comprise the most important 
mechanisms for transmission. In sub-Saharan Africa, there are relatively few injection drug 
users. However, in this region, the high prevalence of unsafe iatrogenic injections within 
healthcare settings may account for significant HCV transmission.  In South Africa, due to the 
screening and testing of blood and blood products, the risk of HCV transmission through blood 
donation is very rare (0.1%) 42. 
HCV may be transmitted through sexual intercourse with an infected person, or from mother to 
infant which is less common.  Transmission is estimated to be less than 5% for each mode 42.  
Clinical     
Hepatitis C is a hepatotropic virus which causes liver disease.  HCV infection can range in 
severity from a mild illness to severe life threatening disease.  Approximately 75-85 % of those 
newly infected develop chronic infection and 60-70% of chronically infected people develop 
liver disease; 5-20% develop cirrhosis and 1-5% die from cirrhosis or hepatocellular carcinoma. 
Studies have shown a link between HCV and 25% of all hepatocellular carcinoma patients 3, 45. 
Diagnosis 
This is based on either antibody detection (HCV IgG), or testing for HCV RNA. Antibody 
detection is commonly used however it cannot differentiate between acute and chronic infection. 
The presence of antibodies against HCV indicates that a person either is or was infected. The 
presence of antibodies is not protective, unlike for HBV.   Confirmatory tests require the use of 
RNA testing 3. 
Surveillance 
A diagnosis of Hepatitis C is a notifiable condition in South Africa (as described previously for 
Hepatitis B). 
Treatment 
Treatment for HCV infection includes the use of antiviral drugs. However, access to treatment is 
limited by high costs and the lack of availability of resources, especially in low to middle income 





There is no vaccine for HCV. Infections can be prevented by avoiding unsafe injections,  blood 
products and healthcare waste, illicit drug use, unprotected intercourse, sharing of sharp personal 
items, tattoos and piercings 3. 
WHO recommends HCV screening for the following: people who received blood, blood 
products or organs before implementation of HCV screening; current or former injection drug 
users; long-term haemodialysis patients; health-care workers; and people living with HIV 3. 
 
1.2.4 HIV and HBV co-infection  
Epidemiology 
Globally, 2-4 million people are co-infected with HIV and chronic HBV. These co-infection 
estimates are influenced by age, geographic differences and the prevalence found in high risk 
populations 1. 
Western Europe has a low prevalence of HIV and HBV infections. The low HBV prevalence is  
due to most HBV infections being acquired in adulthood when chronicity is less likely 1.  
Sexual and injection drug use exposures are responsible for most HIV and HBV infections in 
high income countries. However, chronic HBV infection may be more than ten times higher than 
the population prevalence among some HIV positive individuals in selected high risk groups 1. 
Heterosexual transmission is the predominant mode of transmission for HIV in sub-Saharan 
Africa. The high prevalence of chronic HBV infection is due to perinatal and early childhood 
transmission. HBV infection acquired at an early age is more likely to progress to chronicity. 
This results in a high prevalence of chronic HBV infection among the adolescents and adults at 
risk for HIV 1. 
The epidemiology of both HIV and HBV has been studied in various countries in sub-Saharan 
Africa, but relatively few studies have examined the burden of HIV/HBV co-infection, and the 





The natural history of HBV is modified by HIV. Those with co-infections have higher rates of 
persistence and relapse (re-emergence of HBsAg) and more severe and rapid disease progression 
(including the development of hepatocellular carcinoma).  Acute HBV infection may progress to 
chronicity in the presence of HIV 46.  About 25% of HIV/HBV co-infections will become 
chronic, compared to 5% of chronic infections in those without HIV 47. 
HIV/HBV co-infection requires individual management of patients, as some ARV drugs 
(Tenofovir, Lamivudine and Emtricitabine) display anti-HBV activity 48. 
Immune reconstitution, following initiation of ARVs, can lead to potentially life threatening 
flares of Hepatitis B in HIV/HBV co-infected individuals 39. 
Mother to child transmission in co-infected pregnant women is important. The high HBV viral 
loads in the mother can lead to transmission to the infants, irrespective of infant immunisation 
status. Furthermore, in HIV/HBV co-infected women, there may be a decrease in the transfer of 
protective Hepatitis B antibodies from mother to child.  These women could also have actively 
replicating HBV, which they are likely to transmit to their new-borns 20.   
HIV/HBV co-infected patients lose protective antibodies (HBsAb) faster than HBV infected 
patients without HIV (40% loss in 1 year vs 5% loss in 1 year, respectively) 49, 50. The loss of 
protective immunity may lead to HBV reactivation, or exposure to new HBV infections 48. 
 
1.2.5 HIV and HCV co-infection 
Epidemiology 
The prevalence of HIV/HCV co-infections varies in high income settings (North America and 
Europe), depending on the nature of the cohorts 4. In cohorts with a single predominant risk 
factor for HIV acquisition, the proportion co-infected with HCV depends on that risk factor, e.g. 
HIV/HCV co-infection among urban injection drug users ranged from 84% to 88% 4. In contrast, 
HIV-positive men, whose primary HIV risk factor was sex with other men, had a lower 




There is less published data on the prevalence of HIV/HCV co-infection in low to middle income 
settings. Injection drug use is less common behaviour and heterosexual transmission accounts for 
most new HIV cases. There are few HCV sero-prevalence studies among those who acquire  
HIV through heterosexual transmission, or through exposure to unsafe medical injections 4. A 
review of studies conducted in high risk groups found virtually no association between the 
prevalence of HIV and HCV 42.  There is a paucity of population-based data on the prevalence of 
HIV/HCV co-infection  4.  
Clinical 
HIV co-infection was associated with an accelerated progression of liver disease, increased risk 
of cirrhosis and hepatocellular carcinoma and decreased survival among HCV infected 
individuals, prior to the introduction of ART 4. HCV is associated with a delayed recovery of  
CD4 counts, and may act as a potential risk factor for drug related hepatotoxicity, following 
commencement of ART 4, 51. 
 
1.2.6 HBV and HCV co-infection   
Epidemiology 
Population-based sero-prevalence data on HBV/HCV co-infection is unavailable. Existing 
studies focus on high-risk groups e.g. chronic liver disease patients and injection drug users. 
Studies in high income settings (such as New Zealand and Italy) describe HBV/HIV co-infection 
prevalence ranging from 7% to 10% 4, 52, 53.  
In low to middle income settings where HBV is highly endemic (such as in The Gambia) 3.8% 
of hepatocellular carcinoma patients were found to be co-infected 4, 54. A population-based 
survey in an urban area in Pakistan reported a low prevalence (0.6%) of HBV and HCV co-







The proportion of HBV/HCV co-infected individuals influences the chronic liver disease burden. 
HBV/HCV co-infection in chronic hepatitis patients is associated with more severe liver disease 
than in chronic hepatitis patients with HCV infection alone 4, 56. A meta-analysis found an 
association between HBV/HCV co-infection and hepatocellular carcinoma, suggesting a 
synergistic effect between the two viruses in causing hepatocellular carcinoma 4, 57. Liver related 





1.3 STATEMENT OF THE PROBLEM 
The prevalence of HBV and HCV is higher in HIV positive individuals due to shared 
transmission routes. HIV positive individuals have longer life expectancies as a result of the 
availability of ART. Therefore, morbidity and mortality due to HBV and HCV related conditions 
are becoming increasingly prominent among HIV positive individuals.  Co-infected patients have 
more severe liver disease and increased side effects from ARVs 58-60. 
 
It is therefore important to have epidemiological data on co-infection in HIV and HBV/HCV 
infected individuals.  The data may be used to estimate the impact of hepatitis co-infections in 
HIV positive individuals, which will guide policy makers in terms of screening and prevention 
programs. There is a need for accurate and reliable epidemiological data, especially in a South 
African setting in order to prevent and control infection, transmission and spread 5. 
 
There is limited data on HIV and HBV/HCV co-infections in KZN, despite the high HIV 
prevalence in this population.  Existing studies in this region were performed early in the HIV 
epidemic, prior to the introduction of ART, often in specific high risk groups with small sample 
numbers, and before the availability of validated laboratory tests 5. 
 
With a view to adding to the epidemiological data on HIV and HBV/HCV co-infections, this 
retrospective laboratory database study was conducted in the Department of Virology Laboratory 
(National Health Laboratory Service) at Inkosi Albert Luthuli Central Hospital in Durban to 
determine the prevalence of HIV and HBV/HCV co-infections in KZN from 2002 to 2010.  
1.3.1 Research Questions 
1.3.1.1 What is the sero-prevalence of HIV, and HBV/HCV co-infections in KZN from 2002 to 
2010? 
1.3.1.2 How does the sero-prevalence of HIV, HBV and HCV vary in terms of age, gender and  
between KZN health districts from 2002 to 2010? 




1.4 PURPOSE OF THE RESEARCH 
The purpose of the study was to describe HIV and HBV/HCV co-infections in KZN from 2002 
to 2010 using a laboratory database, to provide public health recommendations. 
 
1.5 SPECIFIC OBJECTIVES OF THE RESEARCH 
1. To describe the socio-demographic profile (age, gender, district of residence) of the study 
population; 
2. To describe the sero-prevalence of HIV, HBV and HCV among the study population; 
3. To describe the sero-prevalence of HIV, HBV and HCV in terms of age, gender and KZN 
health district, from 2002 to 2010; 
4. To describe co-infection between (a) HIV and HBV, (b) HIV and HCV and (c) HBV and 
HCV. 
 
1.6 ASSUMPTIONS UNDERLYING THE STUDY 
 The study population is representative of individuals attending public health facilities in 
KZN. 
 The data entered into the laboratory database was done accurately, and with minimal error.  
 The results of tests were valid. 
 
1.7 OPERATIONAL DEFINITIONS USED IN THE STUDY 
 Sero-prevalence – number of persons in this study population who have a positive serological 
test  for a specific disease 61. 
o HIV sero-prevalence is defined as the percentage of individuals testing positive for 
either HIV antibodies or HIV antigen. 
o HBV sero-prevalence is defined as the percentage of individuals testing positive for 
HBsAg. 





 Age – defined as the age at which the individual had the first test for HIV, HBV or HCV, 
recorded in the database. 
 
 Health district – determined by the health facility location from which the specimen was sent. 
 
1.8 ORGANISATION OF THE REPORT 
This dissertation is divided into six chapters.  
Chapter one provides an overview of HIV, HBV and HCV globally and locally. This chapter 
also outlines the research questions, main objectives and purpose of this study. 
Chapter two outlines the body of knowledge related to HIV/HBV, HIV/HCV, and HBV/HCV 
co-infection. Literature pertaining to each of these topics is critically analysed. 
Chapter three describes the methods undertaken in this study. This includes study design, study 
population, data sources, variables, statistical analysis, internal validity and external validity 
(generalisability), bias and limitations associated with the study. 
Chapter four presents the results of the study. The study population is described which is 
followed by the overall sero-prevalence of HIV, HBV and HCV. Sero-prevalence for each of the 
viruses is further described in terms of age, gender and KZN health district from 2002 to 2010. 
The associations between HIV and HBV, HIV and HCV, and HBV and HCV are determined. 
Chapter five outlines the findings of the study and discusses these results in relation to previous 
studies. 






HIV, HBV and HCV are important global public health problems. This chapter has provided a 







2 CHAPTER II: LITERATURE REVIEW 
2.1 INTRODUCTION 
Several studies have documented the prevalence of HIV and HBV/HCV co-infections in sub-
Saharan Africa.  However, these studies are limited by small numbers and specific high risk 
cohorts. Furthermore, a number of these studies were conducted early in the HIV epidemic and 
prior to the introduction to ART.   
This study contributes to the epidemiological data on HIV and HBV/HCV co-infections in KZN.  
 
2.2 PURPOSE OF THE LITERATURE REVIEW 
The purpose of the literature review was to examine the published literature on the prevalence of 
HIV/HBV, HIV/HCV and HBV/HCV co-infections in South Africa.  
 
2.3 SCOPE OF THE LITERATURE REVIEW 
The scope of the literature review focused on studies that dealt with the prevalence of HIV/HBV, 
HIV/HCV and HBV/HCV co-infections in South Africa. Selected prevalence studies from sub-
Saharan Africa were also reviewed, for the purposes of providing an appropriate context,. 
 
2.4 SOURCES OF LITERATURE REVIEWED 
The PubMed database was searched for studies between 1980 and 2013 pertaining to the 
prevalence of HIV/HBV, HIV/HCV and HBV/HCV co-infections. 
The following search terms were used to find citations relating to the prevalence of HIV/HBV, 
HIV/HCV and HBV/HCV co-infections: “Hepatitis”, “HIV”, “Hepatitis B”, “Hepatitis C”, “co-





2.5 LITERATURE REVIEWED 
2.5.1 Prevalence of HIV/HBV co-infection 
Sub-Saharan Africa 
A summary of the studies described in the literature review, is provided in Table 1. 
A systematic review and meta-analysis of 60 studies (12 639 individuals) conducted in 18 sub-
Saharan African countries reported a median HBsAg prevalence of 12.10% (range 3.9%-70.0%) 
in HIV positive individuals 5.  The weighted mean HBsAg prevalence (based on study size) was 
higher at 14.90% 5.  
The Risk Ratio (RR) for having a positive HBsAg in people with HIV, compared to those 
without HIV, was 1.40 (95% CI 1.16-1.69%), which indicates a 40% increased risk for a positive 
HBsAg in those with HIV, compared to those without HIV 5. The tau squared statistic (where τ2 
>0.1 indicates substantial heterogeneity) was 0.2 5. 
There was no significant difference in HBeAg positivity between those with HIV and those 
without (17.10% vs 15.40%, p = 0.5), based on the findings of thirteen studies 5. 
There are a number of limitations that weaken the internal validity of the study 5. These include 
the observational nature of the reviewed studies (retrospective and cross sectional only) and the 
demonstrated heterogeneity between studies.  Furthermore, the pooled prevalence over a large 
and diverse geographical area may not be a true estimate of the HBV prevalence in those with 
HIV 5. 
The use of HBsAg as a surrogate marker for HBV infection may also underestimate the true 
prevalence of HBV infection, by overlooking the possibility of ‘occult HBV infections’ (positive 
HBV DNA, in the absence of a positive HBsAg), especially in those with HIV 5. However, 
‘occult HBV’ is a rare finding and may have a negligible effect on prevalence 20.   
The lack of an observed association between the prevalence of HBsAg and HIV may be due to 




There may be an inherent selection bias present, as only published studies were included for 
review; the authors did not include data presented solely at conferences or publications in 
regional journals 5. 
The generalisability of the systematic review by Barth is limited by most of the studies being set 
in urban areas, the majority of participants being female and selected study populations (blood 
donors, pregnant women or sex workers) 5. 
The strengths of the study are based on it being the largest systematic review and meta-analysis 
of Hepatitis B/C and HIV co-infection in sub-Saharan Africa, a region which lacks reliable 
epidemiological data. The findings suggest a considerable difference in the prevalence of HBV 
in HIV positive individuals across the region. This has implications for public health prevention 
and treatment strategies 5. 
South Africa 
Lodenyo described a HIV/HBV co-infection prevalence of 6.0% in a prospective cohort of 100 
patients with AIDS who were admitted to a tertiary public sector hospital in urban Johannesburg, 
prior to the national rollout of ART 62. More than a third (35%) of patients had evidence of past 
HBV infection; and half of those with HBsAg positivity were also positive for HBeAg 62.  The 
age range of the patients was 16 to 54 years (mean age = 34.6 years; Standard Deviation (SD) = 
7.5 years) 62. The gender distribution was 52% males, and 48% females  62. The mean CD4 count 
was 141.5 cells/µl (SD = 168.6 cells/µl) 62. 
The findings of the study were comparable to those from higher income countries, and the 
relatively low HBsAg prevalence indicated that the patients were infected when still 
immunocompetent 62. The generalisability of this study was limited by the small number of 
enrolled patients, and that the patients themselves represented a select group (those who were 
admitted to hospital with a diagnosis of AIDS) 62. 
In 2009, Firnhaber reported a HBsAg prevalence of 4.78% in a prospective cohort study of 502 
HIV positive outpatients attending an urban HIV clinic in Johannesburg 63. Nearly  half  (47%) 
of the patients in this study showed some evidence of HBV exposure, which was similar to the 




association between HBsAg and HBeAg 63. The female to male ratio was 2.5:1, with a mean age 
of 37 years (SD 9.1 years) and a CD4 count of 128.6 cells/µl (SD 84.4 µl) 63.  The risk of 
HIV/HBV co-infection was not significantly different in terms of age, gender, race or CD4 count 
63.  
A limitation in both the Lodenyo and the Firnhaber studies was the low CD4 count 62, 63. It is 
possible that the presence of a severely immunocompromised state (characterised by a low CD4 
count) could have potentially decreased the production of antibodies to HBV, leading to a 
misclassification bias in the diagnosis of HBV 63. 
Previous studies have suggested a higher prevalence of HIV/HBV co-infection in rural compared 
to urban areas 64. HBsAg prevalence  among HIV positive adults was found to be 20% in a 
cohort of gold miners from a rural area 58, compared to the 5-6% HBsAg prevalence in HIV 
infected urban cohorts  62, 63. 
Hoffman, in a retrospective cohort study, described a 20% HBsAg prevalence in 537 patients 
enrolled in a workplace ART program in a rural mining community 58.  The majority of the 
patients (94%) were male, with a median age of 41 years, interquartile range (IQR) 36-46 years, 
and a median CD4 count of 146 cells/µl (IQR 79-224 cells/µl) 58.  
The first limitation of the study was that general illness and malnutrition levels of mine workers 
would not be comparable to that found in other low income settings.  Secondly the 
predominantly male cohort was from a number of African countries, therefore the observed 
HIV/HBV co-infection  prevalence may not be generalisable to the rural South African 
population 58. 
In contrast to the Hoffman study 58,  Barth described a very low HBsAg (0.41%) prevalence  in 
248 ARV naïve patients attending a rural clinic in Limpopo 65. The majority of the patients were 
female (63.71%) with a median CD4 count of 273 cells/mm3 (IQR 91-393 cells/mm3) 65. A 
possible reason for the low HBsAg prevalence was that the community may have had limited 
contact with high endemic areas due to geographic, ethnic or cultural factors 65.  This is in 





Boyles described  a HBsAg prevalence of 7.14% in 1765 HIV positive patients, enrolled on ART 
at a  rural clinic in Eastern Cape.  One quarter of the patients were males with a median age of 
31.8 years (IQR 26.3-39.2 years) and a median CD4 count of 207 cells/µl (99-69 cells/µl). Age 
was not found to be associated with HBsAg 64.  
This study was the first to suggest that being male is a risk factor for HIV/HBV co-infection, 
with a crude Odds Ratio (OR)  of 2.64 (95% CI 1.76-3.95%) and an adjusted OR of 2.59 (95% 
CI 1.68-4.00%), p<0.001 in male patients with HIV/HBV co-infection 64. 
There are a few laboratory based HIV/HBV prevalence studies in South Africa 66-68. These 
studies are generally retrospective in nature, have small study numbers and involve the analysis 
of stored sera. 
Mphahlele reported a HBsAg prevalence of 16.2% in 295 stored sera samples from 167 HIV 
positive and 128 HIV negative patients from a  tertiary hospital in Limpopo province 68. This 
was a retrospective, unmatched case control laboratory based study of stored sera  conducted at a 
tertiary hospital in Limpopo.  None of the specimens were from patients vaccinated with the 
HBV vaccine, or on ARVs. The mean age was 34.4 years; range was 15-78 years, and the 
distribution of males to females was almost 50% 68. 
There was a higher prevalence of HBsAg in the HIV negative compared to the HIV positive 
specimens (35.2% vs 16.2%), even though the HIV positive and HIV negative groups were 
exposed equally to HBV 68. 
These paradoxical findings could be attributed to the presence of a selection bias, as HIV 
negative specimens from the same tertiary hospital setting were used as controls. The bias could 
be attributed to the HIV negative specimens being from patients with chronic liver disease who 
were attending the gastroenterology unit at the tertiary hospital. Thus a greater number of HIV 
negative patients would have been HBsAg positive due to the nature of their pre-existing disease. 
The study does not comment on any matching of cases and controls having occurred, which 
could have further contributed to the presence of bias in the findings. 
Lukwhareni documented the findings from a retrospective laboratory based study of stored sera 




Mphahlele 68. The mean age was 37.1 years (range of 14-68 years), and 68% were males 67. The 
CD4 cell counts ranged from 2-1069 cells/µl, with a mean count of 116 cells/µl 67. The sera was 
from patients who were not yet started on ART 67. 
The study found a 22.9% HBsAg sero-prevalence, with an overall 63% having been exposed to 
HBV. This was higher than the prevalence reported by Mphahlele 68. 
Burnett described a statistically significant difference in the prevalence of HBsAg (39.2% vs 
30.1%; OR = 1.49, 95% CI 1.19 – 1.87, p<0.0004) between HIV positive (n = 710) and HIV 
negative (n = 710) pregnant South African women 66. The study design was a retrospective, 
anonymous, matched case–control which was conducted on the stored sera of pregnant women 
that attended public antenatal clinics in Limpopo and the North West Province from 1999 to 
2001 66. 
A major bias in the study is that the study population included only pregnant women that 
attended antenatal clinics. This excluded all non-pregnant women and women who did not attend 
antenatal clinics. A further possible source of bias is the over representation of healthy HIV 
positive pregnant women who regularly use the antenatal facilities 66.  Thus, the study findings 
are not generalisable to the general population. 
The literature review of studies on HIV/HBV co-infection highlighted the following: the 
prevalence of HBsAg varies depending on geographic location, sex, HIV status, age; the type of 
study design, the timing of the study and the location of the study. This emphasizes the need for 






2.5.2 Prevalence of HIV/HCV co-infection 
Sub-Saharan Africa 
A systematic review and meta-analysis conducted by Barth reported 6.90% (9029 participants) 
were co-infected with HIV and HCV 5. The median prevalence across studies was 4.80% (range 
0.0-22.2%) 5. 
The RR for having HCV in those with HIV, compared to those without HIV was 1.60 (95% CI 
1.05-2.45); HIV positive individuals had a 60% increased risk of having HCV, compared to 
those without HIV. The included studies were highly heterogeneous (τ2 = 0.6).  
The limitations which weaken the internal validity of the study have been described previously 
for HBV and are also applicable here 5.  These include the observational nature of the reviewed 
studies (retrospective and cross sectional only) and the demonstrated heterogeneity between 
studies.  The pooled prevalence over a large and diverse geographical area may not be a true 
estimate of the HBV prevalence in those with HIV 5. 
Furthermore, a non-differential misclassification bias (towards the null) may be present in the 
study, as it is not possible to make a distinction between active and spontaneously resolved HCV 
infection solely using HCV serology 5. Thus the prevalence of HCV may be lower than the 
reported prevalence 5. 
A contrasting view from Madhava, in a review of the HCV prevalence in sub-Saharan African 
countries is relevant here 42. In this review, there was almost no association found between HCV 
and HIV in 20 studies that examined HIV/HCV co-infection 42, 69-71. It was also noted that  the 
countries with the highest HIV infection prevalence had the lowest estimated HCV prevalence 42. 
A limitation of the Madhava study is that some of the reviewed studies were conducted  on 
archived blood.  Also, some studies did not indicate when the blood samples were collected. This 
is important due to the changes that have occurred in HCV epidemiology, and the recent 
improvements in HCV diagnostic specificity and sensitivity 42. Another reason for the 
differences in findings between the Madhava 42 and the Barth 5 studies, is that the former was not 






Several studies have demonstrated a low HCV prevalence (approximately 1%-2%), in HIV-HCV 
co-infected patients in South Africa 51, 72. This is in contrast to the finding of a HCV prevalence 
of 13.4% in patients with HIV, as described by Parboosing 73. 
The prevalence of HIV/HCV co-infection was 1.9% in South Africa during a multinational, 
randomized placebo controlled study assessing the safety and efficacy of the addition of 
lamivudine to antiretroviral therapy in 1649 participants 51.  
The study limitations were as follows: the study was conducted in the 1995, prior to the rollout 
of ART, and was not specifically designed to examine HIV/HCV co-infection. The majority of 
the South African participants were Caucasian, which did not reflect the epidemiology of HIV.  
The study only included those patients with a CD4 count of 25-250 cells/µl, so the findings may 
not be representative of all levels of immune deficiency; an Alanine Transaminase (ALT) level 5 
times greater than upper limit of normal was an exclusion criterion, which possibly 
underestimated the sero-prevalence of HIV/HCV co-infection 51. 
Gededzha documented  a HCV sero-prevalence of 1.2% in 653 HIV patients enrolled for ART at 
a tertiary hospital in Pretoria, from 2004 to 2008 72. This study used a retrospective, laboratory 
based design 72. 
Limitations regarding the laboratory diagnosis of HCV were as follows: serological assays did 
not distinguish between acute, chronic and past infection and the low prevalence of HCV 
antibodies could be due to immunosuppression of the patients 72 . Other limitations  included the 
use of stored sera, the insufficient sample volumes and that the study was conducted on patients 
attending a tertiary HIV referral clinic in a hospital setting, which limits its generalisability 72.    
Co-infection with HIV and HCV was found to be rare (1%) in a prospective cohort study 
conducted by Lodenyo on 100 patients (52 males and 48 females, ages 16 to 54 years) with 
AIDS, admitted to a tertiary hospital in Johannesburg 62.    Limitations of this study were 
described earlier. These included the small number of enrolled patients and that the patients 





HIV/HCV co-infection was found to be even lower (0.8%) in a rural cohort of 252 patients in 
Limpopo 65.  Limitations of the study were described earlier and include the predominantly 
female sample and the small numbers of patients 65. 
In contrast to previous HCV prevalence studies  in HIV positive patients, Parboosing reported a  
significantly higher prevalence of HCV among HIV positive patients as compared to those 
without HIV (13.4% vs. 1.73% respectively) OR = 8.8 (95% CI 5.4-14.3) (n = 1937, p < 0.001) 
73. This study was a sero-prevalence survey of all samples submitted for routine HIV testing from 
selected sentinel sites to  a central laboratory which were screened for HCV. The prevalence of 
HCV was 6.4% and that of HIV, 40.2% (n = 1937). Study limitations included a sample bias, as 
specimens were selected from patients in whom an indication existed for an HIV test, but these 
patients may also have risk factors for HCV 73.  
 
2.5.3 Prevalence of HBV/HCV co-infection 
There are few South African studies that have documented HBV/HCV co-infections.  
A case control study of 231 patients being treated for hepatocellular carcinoma at four hospitals 
in Johannesburg, described a HBV/HCV co-infection prevalence of 8.66% in HBV/HCV co-
infected patients 74.  None of the patients with hepatocellular carcinoma were HIV positive 74.  
A study of 110 patients with chronic liver disease, that were treated in a tertiary hospital setting 
in Durban found 1 patient (0.9%) testing positive for both HBV and HCV 43. None of the 
patients in the study were HIV positive 43. 
Limitations to the generalisability of the findings from the two studies include the lack of HIV 
positive patients, the period in which they were conducted (early in the HIV epidemic, and prior 
to the availability of ART); and the lower sensitivity and specificity of the previous assays for 





Table 1: Comparison of studies discussed in the literature review 




Age (years) and  











Age not stated 
 







prevalence 12.1%, RR = 
1.40 95% CI (1.16 – 
1.69) 
HIV/HCV sero-
prevalence 6.9%, RR = 
1.60 95% CI (1.05  - 
2.45) 
Lodenyo 62 Tertiary hospital, 
Gauteng 
Prospective cohort 
100 16-54  years (Range) 
52% Male/ 48% Female 
Urban, in- 
hospital patients 




Firnhaber 63 ARV clinic, Gauteng 
Cross sectional 
537 37 years (Mean) 
44% Male/ 56% Female 
Urban, 
outpatients 
HBsAg 4.8%  HBV sero-
prevalence 
 
Boyles 64 ARV clinic, Eastern 
Cape 
Cohort  
1765 31.8 years (Median) 
25% Male/ 75% Female 
Rural, outpatients HBsAg 7.1 % HBV sero-
prevalence 
 
Hoffmann 58 Workplace ARV 
clinics, South Africa 
Prospective cohort 
537 44 years (Median) 
94% Male/ 6% Female 
 
Mineworkers HBsAg 19.7% HBV sero-
prevalence 
 
Barth 65 ARV clinic, 
Limpopo 
Cohort 
248 40.5 years (Mean) 
36% Male/ 64% Female 
 












295 34.4 years (Mean) 
15-78 years (Range 
50% Male/ 50% Female 
In-hospital 
patients 






based   




192 37 years (Mean) 
14-68 years  (Range) 
32% Male / 68% 
Female  
Outpatients HBsAg 22.9% HBV sero-
prevalence  






1420 Age not stated  
100%  Female 
 
Outpatients HBsAg 6.2%  HBV sero-
prevalence 
 
Madhava 42 sub-Saharan Africa 
Review 
605225 Age not stated 
<20, 20-40, >40 (Age 
groups) 






South and East Africa – 
mean HCV prevalence 
3.0% (range 0.9 – 
40.0%) 
HBV/HCV - no 








1604 18-29, 30-39, 40-49, 
≥50 
(Age groups) 
86% Males/ 14% 
Females 
Outpatients HCV 











653 Not stated 
 
Outpatients HCV 










1937 36.3 years (Mean)  















Retrospective  case 
control 
231 44.8 years (Mean) 
18-82 years (Range) 


































The literature reviewed in this chapter revealed that there is a paucity of studies relating to 




3 CHAPTER III: METHODS 
3.1 INTRODUCTION 
While there is available evidence on HIV and HBV/HCV co-infections in higher income 
countries, these findings are rarely generalisable to a South African setting, due to the specific 
high risk cohorts, and the small study numbers.   
There is a paucity of data regarding HIV and HBV/HCV co-infection in South Africa. This 
research described the overall sero-prevalence of HIV, HBV and HCV, in relation to age, gender 
and KZN health district from 2002 to 2010; and measured the associations between HIV and 
HBV/HCV and between HBV/HCV. 
This chapter describes the type of research carried out. The study design applied is outlined. The 
study population, data sources, statistical analysis, bias and limitations of the research are 
described. 
 
3.2 TYPE OF RESEARCH 
An epidemiological research study of a laboratory database was conducted. 
 
3.3 STUDY DESIGN 
An observational, analytical, retrospective study design was used. 
 
3.4 STUDY SETTING 
The study was conducted in the Department of Virology, National Health Laboratory Service 
(NHLS), at the Inkosi Albert Luthuli Central Hospital, Durban, KZN. The laboratory is 
accredited by the South African National Accreditation System (SANAS) 75 and is the reference 
Virology laboratory for the public health sector in KZN. At the time of the study, the laboratory 
received the majority of specimens for viral tests in KZN (with the exception of 1 hospital that 




centres and 428 clinics in the KZN public health sector. According to Statistics South Africa 
(StatsSA), approximately 10% of the KZN population reported having medical aid coverage; the 
remainder relied primarily on state health-care services 77.  
 
3.5 TARGET POPULATION 
The results of this study could be generalized to all individuals attending public health facilities 
in KZN. 
 
3.6 STUDY POPULATION 
Inclusion criteria:  All individuals who had a HIV or HBV or HCV serological test result (either 
a positive, negative or indeterminate result) in the database from January 2002 to December 
2010 were included in the study.  
 
Exclusion criteria:  All those without a HIV or HBV or HCV serological test result in the 
database from January 2002 to December 2010. 
 
The study population consisted of 507 834 individuals (i.e. all those with HIV, HBV or HCV test 
results from 2002 to 2010). All individuals who fulfilled the inclusion criteria were entered into 
the study, even if one or more data fields were absent. 
 
3.7 SAMPLING 
The study did not use a sampling strategy. All the individual test results that fulfilled the 





3.8 DATA SOURCES 
3.8.1 Measurement instruments/Data collection techniques  
Samples were received in the Department of Virology laboratory accompanied by a request 
form, containing basic demographic and clinical data. In accordance with standardised 
procedures, the data was captured onto the Laboratory Information System (LIS) by laboratory 
data-capturers, using a standard template.  The real time data entry was cross checked to identify 
possible transcription errors, using standard operating procedures in the laboratory 
Patients were uniquely identified by hospital number and specimens were uniquely identified by 
a bar-coded specimen number. The results of laboratory tests for each patient were uploaded 
electronically into the LIS through an interface between the specimen analyser and the LIS 
database which is routinely cross checked manually by laboratory staff, as per the standard 
operating procedures.   
The routine diagnostic serological tests which were done included ELISAs for HBsAg, HBsAb, 
HBeAg, Hepatitis C IgG, and HIV antibody and antigen.  
 
3.8.1.1 Data abstraction  
Study data was abstracted from the LIS database, using the following specified criteria: 
Laboratory tests for which a result was recorded for HIV, HBV and HCV ELISAs from January 
2002 to December 2010. 
Demographic information included age, gender and name of health facility from which the blood 
was sent. 
 
3.8.1.2 Data handling  
The data was downloaded from the Inkosi Albert Luthuli Central Hospital information system  




was created by allocating each health facility to the appropriate district, using information from 
the KZN Department of Health. The following fields were downloaded: hospital number, health 
facility name, age, gender and laboratory result. A unique record number (distinct from the 
hospital number) was allocated sequentially to each downloaded record in order to maintain the 
anonymity of results. The data was imported into the statistical software package (SAS 
Institute©, Cary, North Carolina, USA).  
 
Duplicate entries, defined as patients (identified by their hospital numbers) who had more than 
one result for the same test, were removed as follows: when individuals had more than one result 
for the same test, only one result was analysed: the first positive result when the individual tested 
positive at least once, and the first negative result, when the individual never tested positive. 
 
3.9  VARIABLES 
Demographic variables were allocated as follows:  
 
 Age was a categorical and a continuous variable. 
When age was categorized, the categories were labelled 0-1, 2-4, 5-9 etc. The category 0-1 
included all individuals from birth to less or equal to 1 year of age. The category 2-4 included all 
those individuals greater than 1 year, and less than or equal to 4 years of age, and so forth. 
 
 Gender was a categorical variable. 
 
 Health district was a categorical variable. 
 
Serological variables were as follows: 
 
 HIV –  HIV antibody or HIV antigen; 
 HBV – HBsAg, HBeAg or HBsAb; 





3.9.1 Reliability and validity of the data source 
Sample collection, data capture, serological assays and release of results in the Department of 
Virology were carried out according to accredited procedures. Laboratory methods were 
validated for diagnostic purposes and appropriate internal and external quality control procedures 
were in place. Results from automated instruments were interfaced directly with the LIS so to 
avoid errors due to manual entries of results.  A 10% transcription check was performed to 
minimize errors in situations when manual entry of data is unavoidable 78.  The kits used for the 
ELISA assays have high sensitivity and specificity. The sensitivities and specificities according 
to manufacturer’s package inserts 79 (ADVIA Centaur®, Siemens Healthcare, Munich, Germany) 
are shown in Table 2. 
 
Table 2: Sensitivities and specificities of HIV, HBV and HCV assays that were used in this 
study 
Assay Specificity  
(%, 95% confidence interval) 
Sensitivity 






99.74 (99.60 – 99.84) 
 
99.90 (99.78 – 99.97) 
 
99.91 (99.78 – 99.97) 
100 (99.08 – 100) 
 
100 (99.09 – 100) 
 
100 (99.18 – 100) 
 
 
3.10 BIAS AND LIMITATIONS 
3.10.1 Selection bias 
A pre-existing selection bias is that all the patients in the database represent those visiting public 




The selection bias present may be due to health seeking behaviour by individuals who visit 
public facilities and allow or consent for bloods to be taken for testing.  These patients may have 
a different disease profile from those that do not  go to health institutions at all, or  those that 
refuse testing,  or those that are asymptomatic and do not require testing. Furthermore, there may 
be variations in the clinical indications for performing the tests on each patient.   
 
This selection bias is unavoidable since this research is a retrospective analysis of pre-existing 
data in the LIS.  
 
 
3.10.2 Information Bias 
An information bias present in the data is that the physical location does not refer to individual 
patient’s addresses; rather it refers to the health facility at which the bloods was taken. There 
may also be transcription errors in terms of recording of demographic information such as age or 
sex.   
An information bias relating to the laboratory tests could be due to false positive or false 
negative results. However, this is unlikely due to the high specificity and sensitivity of the 
diagnostic assays and the presence of quality controls and algorithms in place for the 
confirmatory testing of HIV, HBV or HCV. 
Any information bias present will most likely be non-differential in nature and will potentially 
bias results towards the null. 
 
3.10.3 External validity/Generalisability 









The variables age, gender and health district may be potential confounders in the association 
between HIV and HBV/HCV sero-prevalence. 
 
3.11 STATISTICAL ANALYSIS 
3.11.1 Descriptive methods  
Basic procedures in SAS 9.3 (SAS Institute©, Cary, North Carolina, USA)   were used to 
generate descriptive statistics. Graphs were produced in Excel™ 2010 (Microsoft Corporation©, 
Redmond, Washington, USA).  
 
3.11.2 Analytical methods 
Statistical analysis: differences in proportions were determined by the Chi-squared test and OR. 
For the OR, 95% confidence limits were calculated based on a binomial distribution, using the 
SAS (SAS Institute©, Cary, North Carolina, USA) PROC FREQ procedure. The significance of 
changes in sero-prevalence over time was determined by the two-sided Cochrane Armitage 
Trend test. A p value of < 0.05 was regarded as significant.  Statistical advice was sought while 
planning this study.  
 
3.12 ETHICS  
Ethical approval to conduct this study was obtained from the University KwaZulu-Natal 
Biomedical Research Ethics Committee (BE 038/11) (Appendix A).  
 
Consent from individuals was not sought for this study for the following reasons: informed 
consent was not required as the data was anonymised, the data was unlinked to patient 





Approval to conduct the study using data stored in the laboratory information system was 
obtained from the Department of Virology, National Health Laboratory Service (Appendix A).  
 
The study was registered as a research project for the Master of Medicine (Public Health 
Medicine) with the University of KwaZulu-Natal Postgraduate Education and Research 
Committee (Appendix A). 
 
3.13 SUMMARY 
This epidemiological study was a retrospective analysis of laboratory database. The purpose of 
the study was to describe HIV and HBV/HCV co-infection in KwaZulu-Natal from 2002 to 
2010, using a laboratory database to make public health recommendations. In this chapter, the 










4 CHAPTER IV: RESULTS 
4.1 INTRODUCTION 
 
The purpose of this retrospective study of a laboratory database was to describe HIV and 
HBV/HCV co-infection in KZN from 2002-2010. This was done by describing the overall sero-
prevalence of HIV, HBV and HCV; and in terms of age, gender and KZN health district from 
2002 to 2010; followed by measuring the associations in sero-prevalence between HIV and 
HBV; HIV and HCV; and HBV and HCV. 
The study population comprised of all individuals who had a HIV or HBV or HCV serological 
test result (either a positive, negative or indeterminate result) in the database, from January 2002 
to December 2010. 
 
4.2 STUDY SAMPLE 
 
The study did not use a sampling strategy. All the individuals who fulfilled the inclusion criteria 
were included in the study. 
 
4.3 PRESENTATION OF DATA 
 
4.3.1 The socio-demographic profile (age, gender, district of residence) of the study population 
This study analysed the results of 507 834 serological assays (Table 3). The mean age when 
individuals had their first HIV, HBV or HCV test, was 29.34 years, 95% CI (29.30-29.39 years)  
(Table 7 in Appendix B). Most of the results were from individuals in the 25-30 and 35-40 year 
age groups (Table 8 in Appendix B). Further details of the distribution of tests per age category 
for each of the viruses is shown in Table 8 in Appendix B. 
More females than males were tested for each of the viruses (Table 9 in Appendix B) i.e.  




tests compared to males (33.53%) and 53.86% of females had HCV tests compared to 33.99% of 
males (Table 9 in Appendix B). 
Results were available for all 11 KZN health districts. The majority of HIV tests (67.01%), HBV 
tests (66.79%) and HCV tests (55.88%) were from eThekwini district (Table 10 in Appendix B). 
 
Table 3: Number and % of individuals with HIV, HBV or HCV serological tests in the 
study population, from 2002 to 2010 
Number of individuals Number, % of study               
population* 
N = 507 834 (study population i.e. individuals who had 
HIV, HBV or HCV serological tests from 2002 to 2010) 
Individuals with a HIV test 
Individuals with a HBV test 
Individuals with a HCV test 
 
 
266 411 (52.46)  
266 306 (52.44) 
79 216 (15.59) 
 (*> 100%, as some individuals had a serological test for more than one of the above viruses) 
 
4.3.2 HIV, HBV and HCV sero-prevalence for the study population 
The overall sero-prevalence for HIV was 47% (95% CI 46.81-47.19%), HBV was 12.05% (95% 









Table 4: HIV, HBV and HCV sero-prevalence for the study population from 2002 to 2010 
Test HIV positive 
N = 266 411* 




N = 266 306*  




N = 79 126* 












(*Number of individuals tested for the respective virus) 
 
4.3.3 Sero-prevalence of HIV, HBV and HCV in terms of age, gender, health districts and 
time period 
Age and Gender 
The highest sero-prevalence for HIV and HCV was in the 30-35 year age group, 66.44% and 
5.03% respectively. The highest sero-prevalence  for HBV was in the 20-25 year age group 
(15.74%) (Tables 11, 12, 13 in Appendix B). 
The sero-prevalence for HIV was higher in females when compared to males (47.81% vs 
45.98%, p < 0.0001) (Table 14, in Appendix B). For both the hepatitis markers, sero-prevalence 
was higher in males than in females (HBV: 15.54% vs. 9.91%, p<0.0001 and HCV: 4.38% vs. 
3.8%, p<0.0001) (Table 14 in Appendix B). 
Figures 1-3 and Tables 15-20 (Appendix B) show the sero-prevalence per age category for each 
gender. The Figures and Tables illustrate that the peak prevalence of HIV and HCV in females 
occurs at an earlier age than males, while the opposite is true for HBV, when the age categories > 




The 0-1 year age group shows a HBV sero-prevalence of 9.45% (Figure 2, and Table 12 in 
Appendix B).  
 
Figure 1: HIV sero-prevalence (with 95% CI) by age and gender for the study population 
from 2002 to 2010 
 
Figure 2: HBV sero-prevalence (with 95% CI) by age and gender for the study population 





























































































































































































































Figure 3: HCV sero–prevalence (with 95% CI) by age and gender for the study population 
from 2002 to 2010 
 
Health District 
The variations in sero-prevalence for HIV, HBV and HCV per health district are shown in Figure 
4 and Tables 21-23 (Appendix B). The highest HIV sero-prevalence was in uThukela (87.27%), 
the highest HBV sero-prevalence was in Amajuba (38.94%), and Zululand recorded the highest 



















































































































Figure 4: HIV, HBV and HCV sero-prevalence in 11 KZN health districts from 2002 to 
2010 (Source of map 80) 
Time period 2002 to 2010 
Fig 5-8 and Tables 24-26 (Appendix B) show that the sero-prevalence of HIV and HBV has 





In contrast, the sero-prevalence of HCV did not change significantly over time (p>0.5). 
 
Figure 5: HIV, HBV and HCV sero-prevalence for the study population from 2002 to 2010 
 
























































Figure 7: HBV sero–prevalence for the study population from 2002 to 2010 
 
 


























































4.3.4  HIV/HBV, HIV/HCV and HBV/HCV co-infections 
The odds of having markers for Hepatitis B or C infection was increased in HIV positive 
individuals (Table 5).  
Those with HIV had 3.19 times the odds of being positive for HBsAg (OR = 3.19, 95% CI 2.95-
3.44%, p<0.0001), and 2.06 times the odds of being HBeAg positive (OR = 2.06, 95% CI 1.76-
2.40%, p<0.0001), than those without HIV (Table 5).  
Conversely, those with HIV were less likely be positive for HBsAb (OR = 0.36, 95% CI 0.31-
0.42%, p<0.0001) (Table 5).  
Those with HIV infection had 2.91 times the odds of being HCV IgG positive (OR = 2.91, 95% 
CI 2.40-3.53%), than those without HIV (Table 5).  
Of those individuals tested for HBsAg and HCV IgG, 15.76% were seropositive for both markers 
(Table 6). Those with HBV had 1.38 times the odds of being co-infected with HCV (OR = 1.38, 














Table 5: Comparison of hepatitis markers between HIV positive and HIV negative 
individuals, in the study population from 2002 to 2010 










HBsAb positive  
(%) 

























































(*Only among subjects who were tested for the respective marker. HBsAb considered positive 
when antibody titre >10 mIU/mL. HBsAb usually tested after administration of Hepatitis B 
vaccination. HBeAg only tested if HBsAg is positive.) 
 
Table 6: Association between HBV and HCV sero-prevalence in the study population from 
2002 to 2010 
 HBV positive  (%) Odds Ratio (95% CI) p-value 
HCV negative  















More females than males were tested, of the 507 834 individuals who had HIV, HBV or HCV 
tests. The majority of tests were from the eThekwini district.  The overall sero-prevalence of 
HIV was 47.00%, 12.05% for HBV and 4.13% for HCV, for KZN from 2002 to 2010.  The 
highest sero-prevalence for HIV, and HCV was in the 30-35 year age group, while for HBV it 
was in the 20-25 year age group. There was a relatively high sero-prevalence of HBV in the 0-1 
year age group. HIV sero-prevalence was higher in females, while HBV and HCV sero-
prevalence was higher in males. In terms of health districts, uThukela had the highest HIV sero-
prevalence, while Amajuba and Zululand had the highest HBV and HCV sero-prevalence 
respectively. The overall sero-prevalence of HIV and HBV has decreased significantly over time 
(p<0.0001), while there was no significant change in the sero-prevalence of HCV (p>0.5).  
Those with HIV had 3.19 times the odds of being positive for HBsAg (OR = 3.19, 95% CI 2.95-
3.44%, p<0.0001), and 2.06 times the odds of being positive for HBeAg (OR = 2.06, 95% CI 
1.76-2.40, p<0.0001) than those without HIV. Those with HIV were less likely to be positive for 
HBsAb (OR = 0.36, 95% CI 0.31-0.42%, p<0.0001). 
Those with HIV had 2.91 times the odds of being positive for HCV IgG (OR = 2.91, 95% CI 
2.40-3.53%, p<0.0001) compared to those without HIV. Those with HBV had a 1.38 times the 








5 CHAPTER V: DISCUSSION 
5.1 INTRODUCTION 
In this chapter, the sero-prevalence of HIV, HBV and HCV in terms of age, gender and KZN 
health district from 2002 to 2010 is discussed. The demonstrated associations between HIV and 
HBV, HIV and HCV, and HBV and HCV sero-prevalence are analysed.  
The findings of the study are considered in relation to the possible biases and limitations of the 
study design, the data collection process and the results of the study. The generalisability of the 
study is also discussed. 
 
5.2 FINDINGS 
The format of the discussion is similar to that of the results. 
 
5.2.1 The socio-demographic profile (age, gender, district of residence) of the study population 
The demographic characteristics of this study population differ from other studies which have 
documented HIV and HBV/HCV co-infections. 
Size  
This study population is the largest population based study of HIV and HBV/HCV co-infections 
in KZN, and in South Africa (N = 507 834). The sample size of other observational studies 
conducted in South Africa are characterised by relatively smaller numbers (Table 2).  Two 
studies which describe large sample sizes are those of Barth 5 and Madhava 42. Barth performed a 
systematic review and meta-analysis of HIV and HBV/HCV co-infection in sub-Saharan 
countries, which reviewed results from 12 639 HIV/HBV and 9029 HIV/HCV co-infected 
individuals 5.  Madhava conducted a review of HCV infection in sub-Saharan countries, which 
included a review of 16 cohorts from South Africa, with a sample size of 68 931 individuals 42.  





In this study population, the majority of the HIV, HBV and HCV tests were conducted in the 25-
30 and 35-40 year categories. The age range of the study population was broad (from newborn to 
103 years). This is in contrast to previous studies (as shown in Table 2), in which the age range is 
limited by the choice of the study population, such as attendees of ARV or antenatal clinics. 
Gender 
More females than males were tested for HIV, HBV and HCV  in this study population,. This is 
in keeping with several other studies (Table 2) 34, 64-67, 73. The study by Burnett was conducted in 
antenatal clinics, and thus comprised entirely of pregnant females 66. 
Health district 
This study has analysed test results from all 11 KZN health districts. Similar coverage has not 
been attained in other studies (as shown in Table 2). 
 
5.2.2 HIV, HBV and HCV sero-prevalence among the study population 
The overall HIV sero-prevalence described in this study was 47% (95% CI 46.81-47.19%). This 
is higher than the sero-prevalence observed  in the National Antenatal Surveys for KZN, which 
ranged from 37.5% (95% CI 35.2-39.8%) in 2002 to 39.5% (95% CI 38.0-41.0%) in 2010 11, 81, 
82.  A possible reason for the higher sero-prevalence in this study population is that the HIV tests 
were conducted on specimens from individuals who had clinical indications for the HIV tests. 
This is in contrast to the Antenatal Survey, where all consenting woman attending antenatal 
clinics are tested for HIV, whether or not a clinical indication exists. 
The overall HBV sero-prevalence was 12.05% (95% CI 11.92-12.17%) in this study. Previous 
studies have documented a wide range in HBV sero-prevalence 23-25, 27-29 . This variation is 
dependent  on a number of factors, such as when the studies were conducted (pre or post HBV 
vaccine inclusion into the EPI in South Africa; geographic, race and gender differences, the 
choice of the respective study populations, including high risk cohorts and the presence of co-




The overall HCV sero-prevalence was 4.13% (95% CI 3.99-4.27%) in this study, which is higher 
than the mean HCV prevalence of 3.0% (range 0.0-40%) described in the study by Madhava 42.  
A possible reason for the lower prevalence is that a number of the studies in the review,  
included results from HCV assays that were done on samples that had been stored for long 
periods of time 22.  The Madhava review included studies that were conducted relatively early in 
the HIV epidemic 42.  HCV sero-prevalence, like HBV, also differs depending on geography, 
race, gender, the inclusion of high risk populations, and the presence of co-infections, including 
HIV 42. 
 
5.2.3 Sero-prevalence of HIV, HBV and HCV in terms of age, gender, health districts and 
time  
Age 
HIV sero-prevalence was highest (66.44%) in the 30-35 age category (Table 11, Appendix B) in 
this study population. This is similar to the findings from the 2007-2011 National Antenatal 
Surveys, where the highest HIV sero-prevalence is in the 30-34 year category 11, 82. This may be 
a reflection of the epidemiology of the HIV epidemic in South Africa; those infected early on 
with HIV are surviving for longer periods  6. 
HBV sero-prevalence was highest (15.74%) in the 20-25 age category (Table 12, Appendix B).  
This is in keeping with the findings by Kew, that HBV infection in South Africans is highest in 
the young and decreases with increasing age 30.  Studies have shown that patients in the 20-30 
year age group were more likely to have evidence of HBV infection than older age groups 30, 83, 
84.  This increase in prevalence could be associated with the onset of sexual activity and 
continued sexual transmission in this age group 30. 
The relatively high sero-prevalence (9.45%) of HBV in the 0-1 year age category (Figure 2 and 
Table 12 in Appendix B) raises the possibility of ongoing perinatal or postnatal HBV 
transmission. The timing of exposure is of clinical importance since perinatal exposure is 




finding is in contrast to a recent South African study which reported 1.2% (3/303) of children (5-
24 months of age) being HBsAg positive 26. 
HCV sero-prevalence, was highest (5.03%) in the 30-34 year group (Table 13, Appendix B) in 
this study.   This is different to the findings of Madhava, who described median HCV prevalence 
as 1.3% (range 0.0%-11%), 3.0% (range 0.0-28%) and 12% (range 0.0%-55%) in the <20 year, 
20-40, and >40 year age groups respectively 42. The limitations of this study 42 were described in 
Chapter Two . 
Gender 
HIV sero-prevalence was higher in females when compared to males (47.81% vs 45.98%, p < 
0.0001) (Table 14, in Appendix B) in this study. This is in keeping with the findings that females 
are more vulnerable to HIV acquisition than males which could be due to a number of factors, 
such as biological susceptibility (hormonal mechanisms, abnormal genital tract flora or vaginal 
infections), and factors influencing access to preventative and other health services 10. 
HBV and HCV sero-prevalence was higher in males than in females (HBV: 15.54% vs. 9.91%, 
p<0.0001 and HCV: 4.38% vs. 3.8%, p<0.0001) (Table 14 in Appendix B) in this study.  Other 
studies described HBV infection as being more common in South African males than females, 
with a mean ratio of 2.6:1.0: this is applicable to rural and urban settings, as well as to adults and 
children, despite both genders being equally exposed to HBV  28, 30, 85, 86. 
A population based study of HCV prevalence in Egypt reported that females were more likely to 
have cleared HCV infection than males (44.6% v 33.7%, respectively; p < .001) resulting in 
spontaneous resolution 87.  A similar finding is seen with HBV infection, where viral clearance 
from blood is more common among females than males 88.  Possible reasons for the gender 
differences include the role of genetic or hormonal factors 87. 
Health District 
There was variation in HIV, HBV and HCV sero-prevalence across the 11 KZN districts in this 
study. The highest HIV sero-prevalence was in uThukela (87.27%), the highest HBV sero-
prevalence was in Amajuba (38.94%), and Zululand had the highest HCV sero-prevalence 




The variation in HIV sero-prevalence among districts in this study is much greater than that 
observed in the previous National Antenatal Surveys 11, 81, 82. This is most likely due to the 
relatively homogenous study population in the Antenatal Surveys.   
There is also a variation in HBV and HCV sero-prevalence across the districts but there is no 
published data available for comparison. However, the difference in HBV prevalence in rural 
compared to urban areas is documented.  In rural areas, chronic HBV infection is acquired early 
in life which is in contrast to urban areas, where HBV is generally acquired later in life  30. 
Time  
The sero-prevalence of HIV has decreased significantly over time (from 2002 to 2010) (p< 
0.0001) (Figures 5 and 6).  This finding may be due to the national rollout of ART in 2004 which 
greatly improved the uptake of HIV testing. Consequently an increasing number of individuals 
tested positive for HIV and commenced on ARVs. Because there were no further indications for 
formal HIV diagnostic testing, this may have contributed to observed decrease in HIV sero-
prevalence noted in Figures 5 and 6 89, 90.  
A general decline in HBV sero-prevalence is noted over the study period (p<0.0001) (Figures 5 
and 7) which may reflect the long term population benefits of HBV vaccination (introduced into 
the EPI in 1995) 22.  
There was no significant change in the sero-prevalence of HCV (as reflected in the wide 
confidence intervals of each time point, and p> 0.05) (Figures 5 and 8). 
It is considered important to study the sero-prevalence over time to address the criticism directed 
at studies which combine data from numerous time points without considering temporal changes 
in distribution or transmission 91. 
 
5.2.4 HIV/HBV, HIV/HCV and HBV/HCV co-infections 
The odds of having markers for Hepatitis B infection was increased in HIV positive individuals 




Those with HIV infection had 3.19 times the odds of being positive for HBsAg (OR = 3.19, 95% 
CI 2.95-3.44%, p<0.0001) and 2.06 times the odds of being HBeAg positive (OR = 2.06, 95% CI 
1.76-2.40%, p<0.0001) than those without HIV (Table 5).  Existing studies have reported a wide 
variation in HIV/HBV co-infection prevalence, ranging from 0.4% 65 to 22.9% 67. A systematic 
review and meta-analysis conducted by Barth demonstrated a RR of 1.40 (95% CI 1.16-1.69%) 
for having a positive HBsAg among HIV positive individuals, compared to those without HIV 5. 
The systematic review did not show a significant difference in HBeAg prevalence between HIV 
positive and HIV negative individuals 5.  
Those with HIV were less likely be positive for HBsAb (OR = 0.36, 95% CI 0.31-0.42%, 
p<0.0001) (Table 5).  This may reflect the immunosuppressive effects of HIV which may 
eventually lead to the loss of protective antibodies  against HBV infection 48.  This loss of 
protective immunity may result in HBV reactivation or exposure to new HIV infections 48. 
Those with HIV infection had 2.91 times the odds of being HCV IgG positive (OR = 2.91, 95% 
CI 2.40-3.53%), than those without HIV (Table 5). The measures of association observed in 
other studies range from a RR of 1.60 (95% CI 1.05-2.45%) 5 to an OR of 8.8 (95% 5.4-14.3%), 
p < 0.001 73, possibly reflecting differences in study population and design. 
Of those individuals who were tested for HBsAg and HCV IgG, 15.76% were seropositive for 
both markers (Table 6). Those with HBV were found to have 1.38 times the odds of being co-
infected with HCV (OR = 1.38, 95% CI 1.25-1.53%) compared to those without HBV.  This in 
contrast to the studies conducted by Soni 43 and Kew 74 where the prevalence of HBV/HCV co-
infection ranged from 0.91% to 8.66%  respectively (as shown in Table 6). 
 
5.3 VALIDITY 






5.3.2     Internal validity 
The only data source used was the LIS at the Inkosi Albert Luthuli Central Hospital, Department 
of Virology, National Health Laboratory Service.  The Department of Virology is accredited by 
SANAS 75 and is the reference laboratory for KZN.  
 
In the Department of Virology laboratory, specimens are routinely tested as soon as possible 
after being received in the laboratory.  Repeated freezing and thawing of specimens are avoided, 
which reduces the possibility of erroneous results that may arise from such practices 78. 
In accordance with standardized procedures, the demographic and clinical data contained on 
request forms accompanying specimens was captured into the LIS by laboratory data-capturers, 
using a standardized template.  Patients were uniquely identified by a hospital number; 
specimens were uniquely identified by a bar-coded specimen number. The data was cross 
checked by staff to limit the possibility of internal transcription errors. 
The assays done in the laboratory are highly sensitive and specific.  The markers selected for the 
diagnosis of HIV, HBV, HCV are standard serological markers (Table 2). The results of this 
study were based on automated ELISAs which are regarded as gold standards in serological 
diagnosis 78, 79.  
The results of laboratory tests for each patient were uploaded electronically into the database  
and were facilitated by an interface between the specimen analyser and the LIS, and were  cross 
checked manually by laboratory staff.  These measures minimize the possibility of erroneous 
results being entered into the LIS database. 
 
5.3.3 External validity 
The Department of Virology is the reference Virology laboratory for the public health sector in 
KZN, where the study was conducted. The laboratory received the majority of specimens for 
viral tests in KZN. Thus the results of this study are generalizable to individuals attending public 





This study is not generalisable to individuals attending private health  care facilities, or to 
individuals who had no indication for the specific tests to be done, or to those who had 
indications for these tests but had point of care HIV or HBV tests at health facilities (fixed or 
mobile). 
 
The generalisability of this study can be considered to be greater than those studies which used 
small cohorts in particular settings since this study reflects results from a wide geographic 
distribution across KZN and from all levels of public health facilities (including both inpatients 
and outpatients) and over a nine year time  period. 
 
5.4 BIAS AND LIMITATIONS 
The bias and limitations of this study are discussed with regards to design, data collection and 
findings of the study. 
 
The retrospective design of this study makes investigating the timing of infection difficult since 
it was not possible distinguish which infection occurred first: HIV or HBV or HCV infection. 
Also, a retrospective study does not exclude the possibility that individuals may have acute HBV 
and HCV infection.  
 
Selection bias may be due to samples received for HIV testing, based on the presence of risk 
factors for HIV. However, since HBV and HCV share common risk factors with HIV, it is 
possible that the prevalence of HBV and HCV may be overestimated.    
 
The study setting is the Department of Virology which is the accredited central referral 
laboratory in KZN 75. However, there is one hospital that performs HIV serological tests in its 
own laboratory and does not send sera for testing to the Department of Virology at Inkosi Albert 
Luthuli Central Hospital. In addition, results from point of care tests done across KZN for HIV 
and HBsAg were not reflected in the database. 
Information bias may be present as this study analysed only serological markers for HIV, HBV 




results in the window period were not included.  However, the presence of such bias is likely to 
be non-differential in nature, with the measure of association being biased towards the null.  
 
5.5 SUMMARY 
This study is the largest population based study of HIV and HBV/HCV co-infection in KZN and 
in South Africa (N = 507 834). The study documented the overall HIV, HBV and HCV sero-
prevalence in KZN from 2002 to 2010. There were differences in HIV, HBV and HCV sero-
prevalence for age, gender, health district and over time.  There was a higher sero-prevalence for 
HIV and HCV, in the older age group (30-35 years), than for HBV (20-25 years). Also HIV sero-
prevalence was higher in females than in males; in contrast to HBV and HCV.  The 0-1 year age 
group had a relatively high HBV sero-prevalence. Variations in sero-prevalence for HIV, HBV 
and HCV was described in each of the 11 KZN health districts. There was a significant decrease 
in the sero-prevalence of HBV and HIV over time. Those with HIV had more than three times 
the odds of being positive for HBsAg and more than two times the odds of having HBeAg, 
compared to those without HIV. Those with HIV were also less likely to have evidence of 
protective antibodies against Hepatitis B.  Those with HIV had almost three times the odds of 




6 CHAPTER VI: RECOMMENDATIONS AND CONCLUSIONS 
6.1 INTRODUCTION 
 
This study is the largest population based study of HIV and HBV/HCV co-infection in KZN and 
in South Africa (N = 507 834). The study demonstrated differences in HIV, HBV and HCV sero-
prevalence for age, gender, health district and over time (2002 to 2010).  There was a higher 
sero-prevalence for HIV and HCV, in the older age group (30-35 years) than for HBV (20-25 
years).  The 0-1 year age group had a relatively high HBV sero-prevalence. This study showed 
an increased odds of being sero-positive for HBV or HCV, in those with HIV (HBV: OR = 3.19 
and HCV: OR = 2.91).  Those with HIV were also less likely to have evidence of protective 
antibodies against Hepatitis B.  Those with HBV had 1.38 times the odds of being positive for 
HCV, compared to those without HBV. 
 
This chapter makes recommendations based on the findings of this study.   
 
6.2 CONCLUSION 
This study documented the high sero-prevalence of HIV, HBV and HCV over 9 years for KZN. 
This study demonstrated that a significant number of HIV positive individuals are co-infected 
with either HBV or HCV. 
This finding is of clinical relevance since co-infected individuals have more severe hepatic 
disease and are at increased risk of side effects from ARVs.  
This study adds to existing epidemiological data on HIV, HBV and HCV sero-prevalence and 
co-infection, in a South African setting. This data may be used to inform public health policy, 








High HBV sero-prevalence in the 0-1 year group 
Measures to address the finding of a relatively high HBV sero-prevalence in the 0-1 year age 
group involve a comprehensive public health strategy, which includes vaccination, screening, 
monitoring and surveillance.  In the South African EPI, babies receive the Hepatitis B vaccine at 
6, 10 and 14 weeks of age, currently. The recommendation is for an additional  Hepatitis B dose 
to be administered at birth (within 24 hours) as part of the EPI 22  in order to address the 
relatively high sero-prevalence observed  in the 0-1 year age group.  This is in keeping with 
WHO recommendations 92.  
Further recommendations include the screening of pregnant women for Hepatitis B markers 
(HBsAg and HBsAb) and subsequent immunisation of new-borns born to mothers with Hepatitis 
B 22. At present there is insufficient population level data about the perinatal transmission of 
HBV in South Africa and it is not standard practice to screen pregnant women for HBV.  
Current Hepatitis B vaccination coverage in the EPI should be improved.  Recommendations to 
improve Hepatitis B vaccine coverage include addressing programmatic challenges, improving 
monitoring and evaluation, as well as improving awareness of HBV among health care workers 
and health users. Community Care Givers, and Family Health Teams should ensure that Road to 
Health cards are completed and that vulnerable mothers and babies (including mothers without 
antenatal bookings and babies born at homes, and  those in rural areas) should be linked to 
immunisation services and followed up accordingly 22.  
Active surveillance should be expanded by conducting representative nationwide Hepatitis B 
sero-prevalence  surveys in order to ascertain the long-term impact of Hepatitis B vaccination, as 
part of the EPI 37.  Notably, there is no locally available information on the long term 







High HBV sero-prevalence in the 20-25 year age group 
In order to address the high HBV sero-prevalence observed in the 20-25 year age group, it is 
recommended that an adolescent Hepatitis B vaccine dose be added to the vaccination schedule 
for those with incomplete Hepatitis B vaccine records in their Road to Health cards 22. This dose 
should be administered in schools, by nurses from school health teams.  A similar model of 
vaccine delivery is being used for the national rollout of the Human Papillomavirus vaccination 
of female learners in schools in South Africa 93. 
 
High sero-prevalence of HIV/HBV, HIV/HCV and HBV/HCV co-infections 
Recommendations arising from the findings of high sero-prevalence of co-infections include 
screening and vaccination, prevention, early diagnosis and treatment, and linkage to services. 
There should be screening of HIV positive individuals for HBV and HCV in ART programs, 
prior to initiation of ART. Those found to be co-infected with HIV/HBV should receive 
antiretroviral therapy which is also active against HBV. These patients also require careful 
follow up and management due to the potential for complications such as immune reconstitution, 
cirrhosis and hepatocellular carcinoma 39.  These patients should be advised that their household 
contacts and sexual partners are at increased risk for HBV and should be vaccinated, where 
appropriate 39. Patients with HIV/HCV co-infection should also be monitored carefully for 
hepatic and renal complications 73, 94.  
This study reinforces the need to  screen for Hepatitis B infection in those with HIV, and the 
need to vaccinate HIV positive individuals, who screen negative for Hepatitis B, as 
recommended by the Southern African Clinicians Society 95.  HIV positive individuals do not 
respond optimally to the Hepatitis B vaccine and may require booster doses, and continued 
monitoring and follow up 95.  
The high sero-prevalence of co-infections poses a risk to health care workers exposed to multiple 
viral infections that may be occupationally transmitted. It is therefore recommended that the 
National DOH increase the awareness, implementation, monitoring and evaluation of its 




Health care workers should be required to submit proof of their HBV immunity prior to being 
employed and (HBV negative) health care workers who lack immunity should be vaccinated 22, 
96. This would be similar to the National Health System in United Kingdom  which includes 
appropriate support, health education, counselling, provisions for post exposure prophylaxis and 
linkage to relevant health care services.97.   
Trends in the sero-prevalence of co-infection should be monitored on an ongoing basis. An 
example would be including hepatitis markers in the annual South African National Antenatal 
Surveys 11. 
 
Variation in the sero-prevalence of HBV and HCV, by health district and time 
period 
This study demonstrated variation in the sero-prevalence of HBV and HCV by health district and 
over time. It is likely that this variation will continue, due to the heterogeneity in the distribution 
of populations.  This means that is important to have ongoing accurate district based estimates of 
disease burden due to Hepatitis B and C.  In order to do this, the existing system of passive 
notification needs to be strengthened.  Recommendations to address challenges with under 
diagnosis and under reporting involve: improving the reporting format, increasing dissemination 
of surveillance findings to health care workers educating health care workers and students 
regarding the importance of notification in monitoring and planning, as well as the need for 
accurate epidemiological data to inform public health policy 37, 38. 
 
6.4 RECOMMENDATIONS FOR FURTHER STUDY 
 
The high HBV sero-prevalence observed in the 0-1 year age group should be explored in large 
scale, representative prospective cohort studies, to confirm the study findings and to determine 
the underlying reasons for the high sero-prevalence. 
The differences in sero-prevalence observed between districts and between different time periods 




clusters which may inform future targeted health interventions. Models should also be developed 
to predict future trends in the sero-prevalence of these viral infections, so that appropriate 
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Table 7: Age distribution of the study population from 2002 to 2010 
Characteristic 
 
   Years 
 
 




Mean age  (95% CI) 
 
Median age  
 




















(*age at which individual had first serological test for HIV, HBV or HCV recorded in the 
database)  
 
Table 8:  Age categories for individuals with HIV, HBV and HCV serological tests in the 






















40-45   
45-50  
50-55   
55-60  
60-65  




























































































































































































(Those with no 
age data) 
45671  21952  22212  7527  
 
 
Table 9: Gender distribution of individuals with HIV, HBV and HCV serological tests in 
the study population from 2002 to 2010 



















89296     
148404    
28606         
33.53 
55.73       
10.74 
26920 




















Table 10: Number and % of  individuals with HIV, HBV or HCV serological tests in 11 





















District not specified 
1754 (0.66) 







17 796 (6.68) 
762 (0.29) 
883 (0.33) 
44 229 (16.6) 
4058 (1.52) 










28 770 (10.8) 
920 (1.16) 










12 718 (16.05) 
 
Table 11: HIV results, by age categories for the study population from 2002 to 2010 






















































12 924 (65.29) 
14 500 (45.98) 

















16 706 (52.97) 
21 052 (64.97) 
17 590 (66.46) 






















































Total                                           3977 12 5175 11 5307 244 459 
 
Table 12: HBV results, by age categories for the study population from 2002 to 2010 































































10 179 (83.19) 
21 431 (83.20) 
23 798 (84.06) 
38 131 (83.73) 
24 675 (85.62) 
18 333 (87.55) 
13 645 (89.62) 
















































































































































































































Table 14: HIV, HBsAg and HCV IgG results, by gender for the study population from 2002 
to 2010 












































































































p < 0.0001 
 
 





































































































































p < 0.0001 
 
 
89 296  
(33.53) 
 






p < 0.0001 
 
 
















































p < 0.0001 
 
 
39 732  
(93.14) 
 
92.89 – 93.38 
 







p < 0.0001 
 
 















91.75 – 92.40 
 

























91.43 – 92.52 
 













































Table 15: HIV results, by female gender and age categories for the study population from 
2002 to 2010 






















































































12 701 (58.44) 
14 005 (68.83) 





































Total          2077 
 
                  73 792
  











Table 16: HIV results, by male gender and age categories for the study population from 
2002 to 2010 






































































































































Table 17: HBV results, by female gender and age categories for the study population from 
2002 to 2010 





























































15 177 (85.51) 
15 549 (86.66) 
22 045 (86.98) 






































































Table 18: HBV results, by male gender and age categories for the study population from 
2002 to 2010 





















































































31 21 (20.80) 
















































Table 19: HCV results, by female gender and age categories for the study population from 
2002 to 2010 






































































































































Table 20: HCV results, by male  gender and age categories for the study population from 
2002 to 2010 

















































































































































Table 21: HIV results, by health district for the study population from 2002 to 2010 






















































30 446 (68.84) 
828 (47.21) 







15 531 (87.27) 
342 (44.88) 
364 (41.22) 
13 228 (29.91) 
1754  
















136 850 (51.37) 
 
125 215 (47.00) 
 
266 411  
 
Table 22: HBsAg results, by district for the study population from 2002 to 2010 



















































26 328 (91.51) 
 
1580 (38.94) 
































229 421 (86.15) 
 
32 080 (12.05) 
 
255 306  
 
Table 23: HCV IgG results, by district for the study population from 2002 to 2010 








































































































































25 598 (45.16) 
20 225 (44.21) 
15 447 (51.64) 
14 234 (53.42) 
13 770 (57.76) 
12 708 (60.55) 
13 676 (62.73) 
11 739 (59.54) 
 
10 493 (55.26) 
30 605 (53.99) 
25 233 (55.15) 
14 210 (47.51) 































































10 782 (82.55) 
15 164 (84.77) 
18 865 (85.49) 
27 530 (85.71) 
30 425 (87.25) 
39 054 (87.27) 
41 867 (86.01) 













































































10 106 (92.33) 
23 656 (92.60) 
























73 378  
 
3270 
 
79 210 
 
 
 
